Outline
• Sandoz's biosimilar filgrastim development program
• Zarzio's European performance
• U.S. oncologists' expected uptake of biosimilar filgrastim
• U.S. payers' price expectations and strategy to drive uptake
• Competitive landscape for biosimilars in the United States
• Potential differentiation strategies
• Next milestones for the U.S. biosimilar market
• Q&A
Author(s):